Dr. Robert Holloway, MD
Claim this profileAdventHealth Cancer Institute
Area of expertise
Ovarian Cancer
Robert Holloway, MD has run 8 trials for Ovarian Cancer. Some of their research focus areas include:
Peritoneal Cancer
Robert Holloway, MD has run 3 trials for Peritoneal Cancer. Some of their research focus areas include:
Affiliated Hospitals
AdventHealth Orlando
AdventHealth
Clinical Trials Robert Holloway, MD is currently running
Olvi-Vec + Chemotherapy
for Ovarian Cancer
The OnPrime study is a multi-center, randomized open-label phase 3 study evaluating the safety and efficacy of Olvi-Vec followed by platinum-doublet chemotherapy and bevacizumab compared to the Active Comparator Arm with Physician's Choice of chemotherapy and bevacizumab in women diagnosed with platinum-resistant/refractory ovarian cancer (includes fallopian tube cancer and primary peritoneal cancer). This Phase III trial builds on the efficacy and safety data reported in the previous Phase II VIRO-15 trial with promising objective response rate and progression-free survival observed in heavily pre-treated patients with platinum-resistant/refractory ovarian cancer. The phase II results also showed that the intra-peritoneal route of delivery was efficient in generating tumor cell killing and immune activation, and led to clinical reversal of platinum-resistance or refractoriness in this difficult-to-treat patient population.
Recruiting
2 awards
Phase 3
7 criteria
Avutometinib + Defactinib
for Ovarian Cancer
This study will assess the safety and efficacy of avutometinib (VS-6766) in combination with defactinib versus Investigator's choice of treatments (ICT) in subjects with recurrent LGSOC who have progressed on a prior platinum-based therapy.
Recruiting
2 awards
Phase 3
8 criteria
More about Robert Holloway, MD
Clinical Trial Related
3 years of experience running clinical trials · Led 12 trials as a Principal Investigator · 4 Active Clinical Trials
Treatments Robert Holloway, MD has experience with
- Carboplatin
- Paclitaxel
- Defactinib
- Avutometinib (VS-6766)
- Oregovomab
- NovoTTF-100M Device
Breakdown of trials Robert Holloway, MD has run
Ovarian Cancer
Peritoneal Cancer
Fallopian Tube Cancer
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Robert Holloway, MD specialize in?
Robert Holloway, MD focuses on Ovarian Cancer and Peritoneal Cancer. In particular, much of their work with Ovarian Cancer has involved Stage IV patients, or patients who are Stage III.
Is Robert Holloway, MD currently recruiting for clinical trials?
Yes, Robert Holloway, MD is currently recruiting for 4 clinical trials in Orlando Florida. If you're interested in participating, you should apply.
Are there any treatments that Robert Holloway, MD has studied deeply?
Yes, Robert Holloway, MD has studied treatments such as Carboplatin, Paclitaxel, Defactinib.
What is the best way to schedule an appointment with Robert Holloway, MD?
Apply for one of the trials that Robert Holloway, MD is conducting.
What is the office address of Robert Holloway, MD?
The office of Robert Holloway, MD is located at: AdventHealth Cancer Institute, Orlando, Florida 32804 United States. This is the address for their practice at the AdventHealth Cancer Institute.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.